리투아니아 - 리투아니아어 - SMCA (Valstybinė vaistų kontrolės tarnyba)

orion corporation - kvetiapinas - pailginto atpalaidavimo tabletės - 300 mg; 200 mg; 150 mg; 50 mg; 400 mg - quetiapine

리투아니아 - 리투아니아어 - SMCA (Valstybinė vaistų kontrolės tarnyba)

upjohn eesv - atorvastatinas - plėvele dengtos tabletės - 20 mg; 10 mg; 80 mg; 40 mg - atorvastatin

리투아니아 - 리투아니아어 - SMCA (Valstybinė vaistų kontrolės tarnyba)

upjohn eesv - atorvastatinas - kramtomosios tabletės - 40 mg; 20 mg; 10 mg; 5 mg - atorvastatin

리투아니아 - 리투아니아어 - SMCA (Valstybinė vaistų kontrolės tarnyba)

zentiva k.s. - atorvastatinas - plėvele dengtos tabletės - 10 mg; 20 mg - atorvastatin

리투아니아 - 리투아니아어 - SMCA (Valstybinė vaistų kontrolės tarnyba)

egis pharmaceuticals plc - metildopa - tabletės - 250 mg - methyldopa (levorotatory)

유럽 연합 - 리투아니아어 - EMA (European Medicines Agency)

pfizer europe ma eeig - lorlatinib - karcinoma, nesmulkiųjų ląstelių skausmas - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.

유럽 연합 - 리투아니아어 - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artritas, reumatas - imunosupresantai - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

리투아니아 - 리투아니아어 - SMCA (Valstybinė vaistų kontrolės tarnyba)

teva b.v. - rozuvastatinas/ezetimibas - plėvele dengtos tabletės - 10 mg/10 mg - rosuvastatin and ezetimibe

리투아니아 - 리투아니아어 - SMCA (Valstybinė vaistų kontrolės tarnyba)

teva b.v. - rozuvastatinas/ezetimibas - plėvele dengtos tabletės - 20 mg/10 mg - rosuvastatin and ezetimibe

리투아니아 - 리투아니아어 - SMCA (Valstybinė vaistų kontrolės tarnyba)

sandoz d.d. - rozuvastatinas/ezetimibas - plėvele dengtos tabletės - 10 mg/10 mg - rosuvastatin and ezetimibe